FDA grants Inovio accelerated approval for VOCERYQ in adult RRP

On October 30, 2026, the U.S. Food and Drug Administration granted Inovio Pharmaceuticals accelerated approval for VOCERYQ, formerly INO-3107, to reduce surgery frequency in adults with recurrent respiratory papillomatosis. In the supporting RRP-001 efficacy population, 7 of 26 patients, or 27%, needed no papilloma excision during the 12 months after treatment. Inovio expects to begin making the therapy available in approximately 60 days and plans a full commercial launch in the first quarter of 2027.

The approval moves Inovio's first product toward commercialization and creates a potential nonsurgical treatment option for adults with RRP. Continued approval depends on verification of clinical benefit in a confirmatory study, so the regulatory status remains conditional.

  • 1VOCERYQ was approved for use with INOVIO's CELLECTRA 5PSP DNA-medicine delivery device.
  • 2The FDA requires INOVIO to submit a draft confirmatory-study protocol by the end of 2026, with final-protocol alignment expected by mid-2027.
  • 3INOVIO said it expects full field deployment during the first quarter of 2027.
  • 4The RRP-001 study enrolled 32 adults, and all 32 patients completed it.
  • One report additionally attributes a decline in Precigen shares to competitive concerns, but that reaction is not corroborated by the other materials.
  • One report also refers to an $80M court win alongside the FDA decision, but the court matter is not described in the primary approval material.

Sources